05:59 AM EDT, 03/20/2025 (MT Newswires) -- OptiNose ( OPTN ) shares were up more than 61% in premarket activity Thursday after the company overnight said it agreed to be acquired by Paratek Pharmaceuticals in a deal valued at up to $330 million.

The consideration payable to OptiNose ( OPTN ) shareholders is up to $14 per share, including contingent value rights tied to future commercial milestones, the companies said in a joint statement late Wednesday. It represents a 50% premium to Optinose's ( OPTN ) closing trading price on Wednesday.

The move will expand Paratek's commercial portfolio beyond its flagship antibiotic, nuzyra (omadacycline), and strengthen its focus on specialty therapies for primary care providers and specialists.

The acquisition includes OptiNose's ( OPTN ) approved product xhance (fluticasone propionate), a drug-device combination product approved to treat chronic rhinosinusitis. Paratek plans to "accelerate access for xhance beyond specialists to primary care providers maximizing the recent label expansion for CRS in a 10-million-patient market."

OptiNose ( OPTN ) also said late Wednesday it canceled its Q4 earnings conference call scheduled for March 20 following the announcement related to the takeover, which is subject to regulatory approvals.

Price: 9.71, Change: +3.71, Percent Change: +61.83